References/Citations:

**Fc receptor beta chain deficiency exacerbates murine arthritis in the anti-type II collagen antibody-induced experimental model.**  


**Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.**  
Soo-Hong Min et al., Biochemical and Biophysical Research Communications 391 (2010) 1080-1086.

**The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders.**

---

**How the ArthritoMab™ Antibody Cocktail was used:**

Induced Arthritis in C57Bl/6 mice using 2 mg of ArthritoMab Antibody Cocktail and 100 ug LPS.

Arthritis was induced in APRIL-Tg DBA/1 mice using 1.5 mg ArthritoMab per mouse. On day 9, 50 ug LPS was administered. Clinical scores were monitored through day 26.

Induce arthritis in 8- and 10-week-old BALB/c mice. On day 0, mice were injected intraperitoneally with 4 mg of ArthritoMab. On day 3, mice were boosted intraperitoneally with 50 ug of lipopolysaccharide in 200 ul sterile PBS.

Induced arthritis experiments using six-week-old male BALB/c mice.

Induce arthritis in Female BALB/c mice between 8 and 10 weeks of age. Each mouse received a 4mg intraperitoneal injection on day 0 and a 50ug boost of LPS on day 3.

Induce arthritis in BALB/c mice. On day 0, 100 mg/kg (2 mg/mouse) of ArthritoMab was injected to induce arthritis. At day 5 or 3
respectively, lipopolysacharide (LPS) was injected intraperitoneally (50 ug/mouse) to enhance the incidence.

Induce arthritis in genetically modified mice backcrossed to the arthritis-susceptible DBA/1 strain. Each mouse recieved a total of 4mg of ArthritoMab transferred intravenously in two consecutive days. On the fourth day, a 50ug boost of LPS was given by intraperitoneal injection.

Induce arthritis in Male BALB/c mice. Each mouse recieved 25 mg/kg of ArthitoMab through i.v. injection on day 0 and a 2.5 mg/kg boost of LPS given by i.p. 72 h later.